Marksans Pharma Ltd
NSE:MARKSANS

Watchlist Manager
Marksans Pharma Ltd Logo
Marksans Pharma Ltd
NSE:MARKSANS
Watchlist
Price: 293.7 INR -0.02% Market Closed
Market Cap: 133.1B INR
Have any thoughts about
Marksans Pharma Ltd?
Write Note

Marksans Pharma Ltd
Total Liabilities & Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Marksans Pharma Ltd
Total Liabilities & Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Liabilities & Equity CAGR 3Y CAGR 5Y CAGR 10Y
Marksans Pharma Ltd
NSE:MARKSANS
Total Liabilities & Equity
â‚ą29.1B
CAGR 3-Years
27%
CAGR 5-Years
29%
CAGR 10-Years
19%
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
Total Liabilities & Equity
â‚ą467.3B
CAGR 3-Years
19%
CAGR 5-Years
15%
CAGR 10-Years
N/A
Cipla Ltd
NSE:CIPLA
Total Liabilities & Equity
â‚ą346.6B
CAGR 3-Years
10%
CAGR 5-Years
7%
CAGR 10-Years
9%
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
Total Liabilities & Equity
â‚ą881.2B
CAGR 3-Years
8%
CAGR 5-Years
6%
CAGR 10-Years
11%
T
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
Total Liabilities & Equity
â‚ą150.9B
CAGR 3-Years
3%
CAGR 5-Years
2%
CAGR 10-Years
8%
M
Mankind Pharma Ltd
NSE:MANKIND
Total Liabilities & Equity
â‚ą119.6B
CAGR 3-Years
23%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Marksans Pharma Ltd
Glance View

Market Cap
133.1B INR
Industry
Pharmaceuticals

Marksans Pharma Ltd. is a prominent player in the global pharmaceutical landscape, with its roots deeply embedded in the meticulous world of drug formulation and manufacturing. The company weaves its narrative through a robust portfolio that spans various therapeutic segments, including pain management, oncology, cardiovascular health, and anti-diabetic medications. By navigating the complexities of regulated markets such as the United States, the United Kingdom, and Australia, Marksans has engineered a business model that emphasizes quality, compliance, and innovation. This framework allows the company not only to design and develop a diverse array of generic pharmaceutical products but also to efficiently cater to a global clientele through its cost-effective yet high-quality manufacturing processes. Central to Marksans' success is its strategic integration of research and development with flexible manufacturing capabilities, housed in state-of-the-art facilities across Goa and India. These facilities, certified by leading international regulatory bodies, enable Marksans to maintain a competitive edge in both product delivery and diversification. By leveraging strategic partnerships and continuously expanding its product portfolio, it thrives in the dynamic pharmaceutical market. Revenue generation flows seamlessly through its vertically integrated operations, which streamline the journey from drug conception to distribution. Through these concerted efforts, Marksans not only bolsters its financial standing but also contributes significantly to the broader field of global healthcare, aligning economic performance with a commitment to health and well-being.

MARKSANS Intrinsic Value
185.95 INR
Overvaluation 37%
Intrinsic Value
Price

See Also

What is Marksans Pharma Ltd's Total Liabilities & Equity?
Total Liabilities & Equity
29.1B INR

Based on the financial report for Sep 30, 2024, Marksans Pharma Ltd's Total Liabilities & Equity amounts to 29.1B INR.

What is Marksans Pharma Ltd's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 10Y
19%

Over the last year, the Total Liabilities & Equity growth was 26%. The average annual Total Liabilities & Equity growth rates for Marksans Pharma Ltd have been 27% over the past three years , 29% over the past five years , and 19% over the past ten years .

Back to Top